82ODurvalumab in ≥ 3rd-line EGFR mutant/ALK+, locally...

Annals of Oncology 2017 / 04 Vol. 28; Iss. suppl_2

82ODurvalumab in ≥ 3rd-line EGFR mutant/ALK+, locally advanced or metastatic NSCLC: Results from the phase 2 ATLANTIC study

Garassino, M.C., Cho, B-C., Gray, J.E., Mazières, J., Park, K., Soo, R.A., Dennis, P., Huang, Y., Wadsworth, C., Rizvi, N.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
28
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx091.002
Date:
April, 2017
File:
PDF, 82 KB
english, 2017
Conversion to is in progress
Conversion to is failed